Please login to the form below

Not currently logged in
Email:
Password:

AZ's Brilinta approved in Canada

Health Canada has approved AstraZeneca's Brilinta to prevent blood clots in patients with acute coronary syndrome

Health Canada has approved AstraZeneca's (AZ) Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events, such as blood clots, in patients with acute coronary syndrome.

The approval comes seven months after the drug was denied approval by the US Food and Drug Administration (FDA), with studies demonstrating that patients were more likely to experience heart problems with Brilinta than rival drug Plavix (clopidogrel), despite AZ's treatment having greater efficacy.

The FDA did not request additional studies, but did ask for additional analyses of the data from the company's PLATO trial. The drug remains in review in the US, as well as Russia, India and China.

Including Canada, Brilinta has now been approved in 33 countries, including in the European Union under the name Brilique.

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics